CG Oncology, Inc. Common stock logo

CG Oncology, Inc. Common stock(CGON)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 8 days
PROFIT SINCE LAST BUY
+9.45% ▲
LAST CLOSE
$79.47
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CGON

11/20/2026: CGON (2-star) has a low Upturn Star Rating. Not recommended to BUY.

CG Oncology is a late-stage clinical biopharmaceutical company advancing its lead oncolytic immunotherapy candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's primary strength lies in its promising clinical profile and a robust cash position exceeding $1 billion, which supports ongoing regulatory submissions and commercial preparations. Its core investment story centers on the potential approval and commercial rollout of a bladder-sparing therapy for BCG-unresponsive NMIBC. However, the company faces high execution and regulatory risks due to its concentrated product pipeline and lack of current commercial product revenue. CG Oncology suits growth-oriented investors with high risk tolerance who are monitoring upcoming FDA regulatory milestones and clinical readouts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitCG Oncology offers high-growth exposure centered around late-stage clinical catalysts and a potential commercial drug launch.
Momentum investorStrong fit while signal remains positiveStock price movement is highly sensitive to upcoming clinical data readouts and regulatory milestones.
Value investorWeak fitThe company is pre-revenue and unprofitable, making traditional valuation metrics inapplicable.
Dividend investorWeak fitCG Oncology does not pay dividends, reinvesting all capital into clinical development.
Low-risk investorWeak fitClinical-stage biotechnology investing entails high binary regulatory and pipeline risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price swings around trial results and regulatory updates.
Valuation riskMedium / highValuation relies heavily on future clinical success and commercial potential rather than current earnings.
Competition risk (name the main competitor theme, e.g. AI competition)Medium / highOncology markets feature intense competition from established pharmaceutical giants and alternative immunotherapies.
Business qualityMediumThe company possesses promising late-stage assets and a strong cash position, but lacks a diversified commercial portfolio.
Dividend incomeLow / noneNo dividend is paid or expected in the near term.
Execution riskHighSuccess depends entirely on smooth regulatory review, manufacturing scale-up, and commercial execution.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.32B USD
Price to earnings Ratio -
1Y Target Price 109.69
Price to earnings Ratio -
1Y Target Price 109.69
Volume (30-day avg) 1.6M shares
Beta 0.35
52 Weeks Range 37.01 - 93.95
Updated Date 11/20/2026
52 Weeks Range 37.01 - 93.95
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.76

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -48.67%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CGON receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CGON has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+254.7%) is partially offset by negative earnings growth (-82.9%), weak cash generation (FCF margin -3279.2%), weak profitability (net margin -3985.0%).

Financial Health Rating

★★★★★
CGON's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 92.0%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CGON's strongest growth driver at +254.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-82.9%, negative) and free-cash-flow growth (-67.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 112.3% and approximately 77.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.26%, which materially reduces the ownership score.

Top 5 Institutional Investors

RTW INVESTMENTS, LLC 9.53%
T. Rowe Price Investment Management,Inc. 7.41%
Decheng Capital LLC 7.14%
BlackRock Inc 7.01%
Wellington Management Company LLP 5.96%

Unit Economics (Per $1K Revenue)

★★★★★
CGON generates approximately $-150 of gross profit, $-47,221 of operating income, and $-32,792 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CGON has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development & Contract ServicesNominal revenues derived from development and fill-and-finish manufacturing services via acquired operations like Biovire.The company is essentially pre-revenue, as commercial sales have not yet commenced prior to drug approval.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 6.17B
Price to Sales(TTM) 1186.38
Enterprise Value 6.17B
Price to Sales(TTM) 1186.38
Enterprise Value to Revenue 1000.84
Enterprise Value to EBITDA -
Shares Outstanding 89.32M
Shares Floating 68.95M
Shares Outstanding 89.32M
Shares Floating 68.95M
Percent Insiders 0.26
Percent Institutions 112.35

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.